The ligand-activated nuclear receptor peroxisome-proliferator-activatedreceptor-γ (PPARG or PPARγ) represents a potential targetfor a new generation of cancer therapeutics, especially in muscle-invasiveluminal bladder cancer where PPARγ is a critical lineage driver.Here we disclose the discovery of a series of chloro-nitro-arene covalentinverse-agonists of PPARγ that exploit a benzoxazole core toimprove interactions with corepressors NCOR1 and NCOR2. This evidence concerns the gene NCOR2 and cancer.